Compositions for the prevention or treatment of disseminated intravascular coagulation, and inhibitors of IL-8 and IL-17 production.

JP7871989B2Active Publication Date: 2026-06-09SAITAMA MEDICAL UNIVERSITY
View PDF 2 Cites 0 Cited by

Patent Information

Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
SAITAMA MEDICAL UNIVERSITY
Filing Date
2022-01-17
Publication Date
2026-06-09

AI Technical Summary

Benefits of technology

【0010】 本発明によると、従来における前記諸問題を解決し、前記目的を達成することができ、優れた好中球走化性因子及びその誘導因子の産生抑制作用を有し、好中球細胞外トラップ(NETs)により引き起こされる播種性血管内凝固症候群を予防又は治療することができる播種性血管内凝固症候群の予防又は治療用組成物を提供することができる。

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007871989000034
    Figure 0007871989000034
  • Figure 0007871989000035
    Figure 0007871989000035
  • Figure 0007871989000036
    Figure 0007871989000036
Patent Text Reader

Abstract

A prophylactic or therapeutic composition for disseminated intravascular coagulation syndrome, the composition comprising, as an active ingredient, at least one selected from adenosine A2a receptor antagonists and dopamine D2-like receptor agonists.
Need to check novelty before this filing date? Find Prior Art

Claims

1. It contains an adenosine A2a receptor antagonist as an active ingredient, A composition for the prevention or treatment of disseminated intravascular coagulation, characterized in that the adenosine A2a receptor antagonist is at least one selected from istradefylline and AB928.

2. The composition for the prevention or treatment of disseminated intravascular coagulation according to claim 1, wherein the adenosine A2a receptor antagonist suppresses the production of at least one of IL-8 and IL-17.

3. The composition for the prevention or treatment of disseminated intravascular coagulation according to claim 1 or 2, wherein the disseminated intravascular coagulation is caused by an infection.

4. The composition for the prevention or treatment of disseminated intravascular coagulation according to claim 3, wherein the infectious disease is COVID-19.

5. Contains an adenosine A2a receptor antagonist as an active ingredient, An IL-8 and IL-17 production inhibitor characterized in that the adenosine A2a receptor antagonist is at least one selected from istradefylline and AB928.